Methylcellulose
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Methylcellulose: From Bulk-Forming Agent and Excipient to Osteoarthritis
One-Sentence Summary
Methylcellulose is a non-absorbed cellulose ether, used as a bulk-forming agent, viscosity agent, hydrogel matrix and excipient. The TxGNN model predicts it may be useful for osteoarthritis, but the supporting evidence is weak: 2 clinical trials and 19 publications were retrieved. In these, methylcellulose acts as a carrier or excipient rather than as the tested active drug, so any therapeutic effect of methylcellulose itself is unverified.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the local registration record (bulk-forming agent / excipient use per the evidence pack) |
| Predicted New Indication | Osteoarthritis |
| TxGNN Prediction Score | 95.21% |
| Evidence Level | L4 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Methylcellulose is a non-absorbed cellulose ether with no established pharmacological action against osteoarthritis. The high TxGNN score (0.952) is a knowledge-graph prediction, not a demonstrated effect.
The literature links methylcellulose to osteoarthritis mainly as a delivery vehicle or scaffold. It carries nanozymes, Timp3, celecoxib, meloxicam-type NSAIDs and cell therapies in injectable or transdermal hydrogels. The two retrieved trials appear to test curcumin-type products, with methylcellulose likely present as an excipient or placebo component. The graph association is therefore probably driven by formulation use, not by methylcellulose acting as a therapy.
The other nine predicted indications are weaker still:
- Enterocolitis, alopecia, pseudoachondroplasia, hypotrichosis (two types), diffuse alopecia areata and exercise-induced malignant hyperthermia: prediction only, with no trials or literature and no plausible mechanism.
- Insomnia: five trials were retrieved, but all are supplement or behavioural studies that do not test methylcellulose.
- Osteoarthritis susceptibility: the single supporting paper is a preclinical cartilage-resurfacing study that duplicates the osteoarthritis evidence.
Clinical Trial Evidence
Both trials are graded C (not direct efficacy evidence for methylcellulose).
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01478997 | Phase 1/2 | Completed | 76 | Double-blind, placebo-controlled study of Flexsure in moderate knee osteoarthritis. Methylcellulose is not named as the tested intervention and is probably a formulation component. |
| NCT04207021 | NA | Unknown | 134 | Curcumin-based food supplement for pain and inflammation in osteoarthritis. Methylcellulose is at most an excipient. |
No SANCTR or PACTR registrations were identified.
Literature Evidence
Most items are preclinical formulation studies. The evidence pack classifies the study type as preclinical for the first seven papers in the table. For the last three, the pack marks it as pending or leaves the design unverified. Several papers concern carboxymethylcellulose, a related but different compound. Publications on unrelated topics (for example canine and equine studies, wound dressings and a joint implant) are omitted.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40354857 | 2025 | Preclinical | Int J Biol Macromol | Transdermal F127/methylcellulose hydrogel carrying nanozymes for osteoarthritis. Methylcellulose is the carrier. |
| 41054792 | 2025 | Preclinical | Artif Cells Nanomed Biotechnol | Injectable methylcellulose-carboxymethyl chitosan hydrogel delivering amniotic fluid stromal cell spheroids for cartilage regeneration. |
| 36079990 | 2022 | Preclinical | Nanomaterials (Basel) | Proanthocyanidin transferosomes in a 4% methylcellulose gel for osteoarthritis. Methylcellulose is the gel base. |
| 32027902 | 2020 | Preclinical | Int J Biol Macromol | Injectable carboxymethyl chitosan-methylcellulose-pluronic hydrogel encapsulating meloxicam nanoparticles. |
| 26752990 | 2015 | Preclinical | Res Pharm Sci | Iontophoretic delivery of celecoxib from gels, some containing methylcellulose derivatives. |
| 37321710 | 2023 | Preclinical | Carbohydr Polym | Sulfated carboxymethylcellulose with Timp3 attenuates osteoarthritis (carboxymethylcellulose, not methylcellulose). |
| 25468298 | 2015 | Preclinical | J Biomech | Polymers including carboxymethylcellulose used to resurface damaged cartilage and restore compressive properties. |
| 39486930 | 2025 | Not classified in pack | Carbohydr Polym | Stimuli-responsive methyl cellulose-based injectable hydrogels for controlled release. General materials work. |
| 20060726 | 2011 | Clinical (design not classified in pack) | The Knee | Hyaluronate/carboxymethylcellulose anti-adhesion gel after bilateral total knee arthroplasty (31 patients). It concerns post-surgical range of motion and pain, not methylcellulose. |
| 30767746 | 2020 | Formulation study (design not verifiable from title) | Curr Rheumatol Rev | Herbal topical patch containing curcumin and arnica. The active agents are not methylcellulose. |
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| E1246 (OM) | Medigel | Suspension | Not stated in the record |
The record shows no manufacturer or approved indication text. The registration number format differs from the usual SAHPRA “Reg. No.” style, so it should be verified against the SAHPRA register.
Safety Considerations
- Drug Interactions: No interactions were found in the DDI query (0 records). This is not evidence that none exist.
Please refer to the SAHPRA-approved Professional Information (PI) for warnings and contraindications. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The score is high, but the evidence is only L4. Methylcellulose appears in the osteoarthritis literature as a delivery vehicle, and neither trial tests it as an active drug. There is no mechanistic basis for a direct therapeutic effect, and no safety data (SAHPRA PI) are available to screen the candidate.
To proceed, the following is needed:
- The SAHPRA package insert (warnings, contraindications, approved indication), which is a blocking gap
- Mechanism of action data from DrugBank
- Intervention roles for NCT01478997 and NCT04207021 checked on the registry records, to confirm whether methylcellulose is only an excipient or placebo component
- Verification of the Medigel registration number and indication against the SAHPRA register
- Any direct comparative evidence of methylcellulose (alone, not as a carrier) in osteoarthritis. Without it, this candidate should not advance.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.